TipRanksStock Market NewsPSNL NewsPersonalis (PSNL) Receives a Hold from Needham

Personalis (PSNL) Receives a Hold from Needham

Needham analyst Michael Matson maintained a Hold rating on Personalis (PSNLResearch Report) today. The company’s shares closed last Thursday at $12.04, close to its 52-week low of $11.62.

According to TipRanks.com, Matson is a 5-star analyst with an average return of 10.3% and a 55.3% success rate. Matson covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Cardiovascular Systems, and Zimmer Biomet Holdings.

Personalis has an analyst consensus of Moderate Buy, with a price target consensus of $33.75.

See Insiders’ Hot Stocks on TipRanks >>

Based on Personalis’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $22.26 million and GAAP net loss of $17.67 million. In comparison, last year the company earned revenue of $19.82 million and had a GAAP net loss of $9.55 million.

Based on the recent corporate insider activity of 50 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of PSNL in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Personalis, Inc. provides genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. The company was founded by Euan A. Ashley, Michael Snyder, Atul J. Butte, John S. West, and Russ B. Altman in 2011 and is headquartered in Menlo Park, CA.

Read More on PSNL:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More